The deal focuses on ARV-471, currently in phase 2 testing for advanced breast cancer patients whose tumours expresses oestrogen receptors – so are hormone sensitive – but test negative for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback